ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
36.26
0.00%
US Tech 100
19,890.00
0.22%
S&P 500
5,631.22
0.28%
US Dollar vs CAD
1.36857
0.05%
Bitcoin
63,721.25
-1.74%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Alzamend Neuro Inc (ALZN)

  7. Alzamend Neuro Inc (ALZN) News

ALZN

Alzamend Neuro (ALZN)

Alzamend Neuro Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALZN
DateTimeSourceHeadlineSymbolCompany
04/03/20237:00AMBusiness WireAlzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s TypeNASDAQ:ALZNAlzamend Neuro Inc
03/31/20233:38PMEdgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ALZNAlzamend Neuro Inc
03/22/20233:31PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALZNAlzamend Neuro Inc
03/22/20237:00AMBusiness WireAlzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’sNASDAQ:ALZNAlzamend Neuro Inc
03/16/20233:31PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALZNAlzamend Neuro Inc
03/16/20237:00AMBusiness WireAlzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business UpdateNASDAQ:ALZNAlzamend Neuro Inc
03/15/20233:32PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALZNAlzamend Neuro Inc
02/28/20233:34PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
02/03/20233:34PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALZNAlzamend Neuro Inc
01/26/20237:00AMBusiness WireAlzamend Neuro to Present at Sequire Biotechnology ConferenceNASDAQ:ALZNAlzamend Neuro Inc
01/04/20237:00AMBusiness WireAlzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical TrialNASDAQ:ALZNAlzamend Neuro Inc
12/28/20227:00AMBusiness WireAlzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimer’s TypeNASDAQ:ALZNAlzamend Neuro Inc
12/23/20223:31PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
12/20/20223:31PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
12/12/20223:32PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALZNAlzamend Neuro Inc
11/21/20223:31PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
11/16/20225:31AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALZNAlzamend Neuro Inc
11/15/20223:31PMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ALZNAlzamend Neuro Inc
11/15/20223:31PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
11/15/20227:00AMBusiness WireAlzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic PipelineNASDAQ:ALZNAlzamend Neuro Inc
11/03/20223:31PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
11/01/20223:37PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
10/31/20223:31PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALZNAlzamend Neuro Inc
10/31/20227:00AMBusiness WireAlzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s TypeNASDAQ:ALZNAlzamend Neuro Inc
10/14/20223:31PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
10/07/20223:31PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
10/05/20227:00AMBusiness WireAlzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s SubjectsNASDAQ:ALZNAlzamend Neuro Inc
10/02/20222:15AMTipRanksAlzamend Neuro (ALZN) Gets a Buy from Univest SecuritiesNASDAQ:ALZNAlzamend Neuro Inc
09/29/20223:31PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALZNAlzamend Neuro Inc
09/29/20227:00AMBusiness WireAlzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s TypeNASDAQ:ALZNAlzamend Neuro Inc
 Showing the most relevant articles for your search:NASDAQ:ALZN

Your Recent History

NYSE
INVH
Invitation Homes
BIT
UC610D
Unicredit Bank
BIT
UB5FVN
Unicredit Bank
EU
MFEC
Amundi MSCI EMU UCITS ET...
LSE
0LYX
Stalexport Autostrady
LSE
0MWI
Ubs Etfblmbrgbrcls Us Li...
TSX
CFLX
CIBC Flexible Yield ETF
COIN
DODOGBP
DODO bird
BOV
NTCO3M
NATURA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved